Caris Life Sciences, Inc. (CAI) has a negative trailing P/E of -460.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 125.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -0.22%, forward earnings yield 0.79%. PEG 1.97.
Criteria proven by this page:
Overall SharesGrow Score: 55/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2015 | 21.7 | -0.39 | 1.26 | 2.33 | - |
| 2016 | 90.2 | -1.19 | 1.18 | 1.84 | - |
| 2017 | 7.5 | 0.01 | 0.96 | 1.55 | - |
| 2018 | 7.1 | 1.15 | 0.79 | 1.28 | 0.59% |
| 2019 | 16.3 | -0.29 | 0.73 | 1.21 | 1.75% |
| 2020 | 18.1 | -1.83 | 0.72 | 1.71 | 3.52% |
| 2022 | -22.2 | 0.00 | -4.19 | 27.60 | - |
| 2023 | -20.9 | -1.31 | -3.32 | 23.29 | - |
| 2024 | -25.3 | -0.52 | -2.85 | 17.30 | - |
| 2025 | -83.9 | 2.83 | 78.14 | 55.55 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2015 | $1.28 | $249.67M | $26.84M | 10.7% |
| 2016 | $0.31 | $294.35M | $6M | 2% |
| 2017 | $3.68 | $348.39M | $72.06M | 20.7% |
| 2018 | $3.97 | $432.1M | $78.6M | 18.2% |
| 2019 | $1.72 | $416.54M | $31.01M | 7.4% |
| 2020 | $1.55 | $294.01M | $27.73M | 9.4% |
| 2022 | $-1.57 | $258.49M | $-320.83M | -124.1% |
| 2023 | $-1.82 | $306.13M | $-341.42M | -111.5% |
| 2024 | $-2.70 | $412.26M | $-281.89M | -68.4% |
| 2025 | $-1.90 | $812.03M | $-537.96M | -66.2% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.16 | $0.14 – $0.19 | $1.01B | $993.77M – $1.02B | 6 |
| 2027 | $0.40 | $0.26 – $0.48 | $1.23B | $1.22B – $1.25B | 6 |
| 2028 | $0.71 | $0.44 – $0.97 | $1.45B | $1.44B – $1.45B | 6 |
| 2029 | $1.07 | $1.05 – $1.09 | $1.68B | $1.66B – $1.7B | 4 |
| 2030 | $1.16 | $1.14 – $1.18 | $1.85B | $1.82B – $1.87B | 2 |
